Resources

In part 1 of this Exclusive Interview, Dr. Yehuda Handelsman talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the reasoning behind changes to cholesterol goals.

In part 2 of this Exclusive Interview, Dr. Yehuda Handelsman talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the actual cost to the lives of patients who are put on more expensive, but life-saving, diabetes drugs.

In part 3 of this Exclusive Interview, Dr. Yehuda Handelsman talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about his LDL recommendations according to the patient and varying health events.

In part 4 of this Exclusive Interview, Dr. Yehuda Handelsman talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about safely lowering patient A1c to their particular goal without hypoglycemia.

In part 5 of this Exclusive Interview, Dr. Yehuda Handelsman talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the more exciting diabetes technology developments.

In part 6, the conclusion of this Exclusive Interview, Dr. Yehuda Handelsman talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the ultimate good that came from the failure of Avandia.

As I am working with patients, I have so many thoughts about how different each patient is. I also have thoughts about how in this day and age, with all we have available, some people who have had diabetes for oh so many years still have no clue how to manage their diabetes.

In part 3 of this Exclusive Interview, Dr. Swapnil N Rajpathak talks with Diabetes in Control Publisher Steve Freed during the ADA 2017 Scientific Sessions in San Diego, CA about patient claims of hypoglycemia while on DPP4 treatment.

In this week's Homerun Slides, a closer look at heart failure.

OSA management: OSA should be treated promptly and the aim of treatment is to reduce the morbidity and mortality associated with this condition. Weight loss and positional treatment (i.e., avoiding the position in which most episodes occur, which is usually the supine position) are important aspects of treatment. As with all obesity-related disorders, weight loss (regardless of the means) can result in significant improvements in OSA. In a randomized controlled trial of intensive lifestyle intervention in 264 patients with OSA and T2DM (the Sleep AHEAD study), weight loss of 11 kg on average in the treatment group resulted in a reduction in the AHI of about 10 events per hour.